Gemzar
(gemcitabine hydrochloride)Phase 3Small molecule
Gemcitabine is a chemotherapy drug used to treat various types of cancer, including pancreatic cancer, lung cancer, and breast cancer, by slowing or stopping the growth of cancer cells.[1] Gemzar is currently being investigated across 27 indications[3], with its most advanced program in Phase 3.[1]
Gemzar is one of 371 small molecule programs targeting Liver Cancer. It is currently in Phase 3.
27
Indications
480
Total Trials
7
Active Trials
370
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 27 indications
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Gemzar
GGynecologic Oncology Group
Phase 3
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Active Comparator
ModernaPreclinical
PEG-Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Cyclophosphamid
EEssen Biotech
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer46 trials
Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer
Completed·—·Phase 2·NCT00602602·19 enrolled
Show 43 more trials
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Terminated·—·Phase 2·NCT01897454·23 enrolled
Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
Completed·IInterdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft·Phase 2·NCT00335543·254 enrolled
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00268411·80 enrolled
Non-Small Cell Lung Cancer32 trials
Show 29 more trials
Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003589·450 enrolled
Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Unknown status·IIstituto Nazionale per lo Studio e la Cura dei Tumori·Phase 3·NCT00003447·630 enrolled
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Completed·—·Phase 2·NCT00970684·13 enrolled
Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer
Terminated·—·Phase 2·NCT00530634·3 enrolled
Lymphoma11 trials
Show 8 more trials
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Completed·—·Phase 1/2·NCT00863369·33 enrolled
Bladder Cancer9 trials
Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer
Unknown status·FFondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy·Phase 3·NCT00054626·700 enrolled
Show 6 more trials
Breast Cancer8 trials
Show 5 more trials
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
Unknown status·—·Phase 3·NCT00070278·800 enrolled
59 more indications
Advanced Cancer7 trials
Combination Chemotherapy in Treating Patients With Advanced Cancer
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00003707·22 enrolled
Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer
Unknown status·TThe University of Texas Health Science Center, Houston·Phase 1/2·NCT00004063·30 enrolled
Show 4 more trials
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00006351·34 enrolled
Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer
Completed·—·Phase 1·NCT00004220
Patients With Advanced Solid Tumors6 trials
Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors
Terminated·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 1·NCT00049608·51 enrolled
Show 3 more trials
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT00014456·35 enrolled
Cancer of the Pancreas5 trials
Primary Peritoneal Cancer3 trials
Fallopian Tube Cancer3 trials
Chemotherapy3 trials
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT00014274·238 enrolled
Biliary Tract Cancer3 trials
Kidney Cancer3 trials
Peritoneal Cancer2 trials
Metastatic Colorectal Cancer2 trials
Malignant Mesothelioma2 trials
Small Cell Lung Cancer2 trials
Soft Tissue Sarcoma2 trials
Cholangiocarcinoma2 trials
Metastatic Solid Tumors2 trials
Unresectable Solid Tumor2 trials
Ovarian Epithelial Cancer2 trials
Recurrent Cancer2 trials
T-cell non-Hodgkin lymphoma1 trial
Transitional Cell Carcinoma1 trial
Bladder Urothelial Cancer1 trial
Triple-Negative Breast Cancer1 trial
Acute Lymphoblastic Leukemia1 trial
Relapsed or Refractory1 trial
Epithelial Tumor1 trial
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
Completed·—·Phase 1·NCT00004082
Ovarian Cancer1 trial
Recurrent or Refractory1 trial
Squamous Cell Cancer1 trial
Lymphoid Malignancies1 trial
Chronic Myelomonocytic Leukemia1 trial
HER2-Positive Solid Tumor1 trial
Nasopharyngeal Cancer1 trial
Refractory Solid Tumors1 trial
Biliary Cancer1 trial
Breast1 trial
Chemotherapeutic Agents in Brain/Breast
Completed·—··NCT00795678·10 enrolled
Chondrosarcoma1 trial
Recurrent or Refractory Solid Tumors1 trial
Germ Cell Tumor1 trial
Acute Myeloid Leukemia1 trial
Locally Advanced Cancer1 trial
Urothelial Cancer1 trial
Uterine Cancer1 trial
Stereotactic Body Radiation Therapy1 trial
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
Completed·—·Phase 1·NCT01652794·12 enrolled
Pancreatic Ductal Adenocarcinoma1 trial
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 3·NCT07165951·566 enrolled
Second-line Treatment1 trial
Elderly Patients1 trial
Urinary Tract Cancer1 trial
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Completed·—·Phase 2·NCT01191892·82 enrolled
Cancer of the Head and Neck1 trial
Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00017498·21 enrolled
Mantle Cell Lymphoma1 trial
Locally Advanced Head and Neck Cancer1 trial
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
Completed·—·Phase 2·NCT00544414·31 enrolled
Cancer of the Esophagus1 trial
Gallbladder Cancer1 trial
Advanced Solid Tumors1 trial
Solid Tumors1 trial
Radiation Therapy1 trial
Metastatic Urothelial Cancer1 trial
Colorectal Cancer1 trial
Multiple Myeloma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for gemcitabine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- DNA Polymerase (alpha/delta/epsilon) Inhibitor; Ribonucleoside-Diphosphate Reductase RR1 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- GGynecologic Oncology Group